Poly (I:C):Kanamycin (1:1) (sodium) 

Poly (I:C):Kanamycin (1:1) sodium is an isometric complex of Poly (I:C) (HY-135748) and Kanamycin (HY-16566). Poly(I:C) sodium, a synthetic analog of double-stranded RNA, is a TLR3 and retinoic acid-inducible gene I receptor (RIG-I and b>MDA5) agonist. Poly(I:C) sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses and induce apoptosis in cancer cells^[1][2]. Kanamycin is an orally active antibacterial agent (Gram-negative/positive bacteria) that inhibits translocation and causes miscoding by binding to the 70S ribosomal subunit. Kanamycin shows good inhibitory activity against Mycobacterium tuberculosis (susceptible and drug-resistant) and Klebsiella pneumoniae, and can be used in the research of tuberculosis and pneumonia^[3][4][5][6].

TLR3^[2], RIG-I^[2], MDA5^[2], apoptosis^[2]

Poly (I:C) sodium (20 ng/mL; 24 hours; WM793, WM278, WM239A, WM9 and 1205Lu cells) treatment strongly reduces viability from 100% in controls to 20%–50% within 24 hours^[1].
Poly (I:C) sodium (200 ng/mL; 24 hours; 1205Lu cells) treatment induces apoptosis in 1205Lu cells^[1].
Poly (I:C) sodium (3 ng/mL; 24 hours; 1205Lu cells) treatment induces IFN-β expression in melanoma cells. Silencing of RIG-I and MDA-5 confirmed that induction of IFN-β by Poly (I:C) sodium required RIG-I and MDA-5, respectively, and that required IPS-1^[1].
Poly (I:C) sodiumd (5 ng/mL; 24 hours; 1205Lu cells) treatment reveals active subunits of caspase-9 and caspase-8 in melanoma cells^[1].

Kanamycin (0.1-100 μg/mL; 2 weeks) exhibits good antibacterial activity (MIC=1-5 μg/mL) to various strains of mycobacteria in vitro^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Poly (I:C) sodium treatment inhibits tumor growth in NOD/SCID immunodeficient mice injected with 1205Lu cells. The level of human DNA is 50% lower in mice treated with Poly (I:C) sodium^[1].

Kanamycin (2, 4 mg/kg; s.c.; once daily, 6 times a week for 3 weeks) inhibits growth of bovine tubercle bacilli in lung and spleen of mice^[3].
Kanamycin (1.25, 5 mg/kg; s.c.; single (at 3 h after infection)) inhibits the multiplication of K. pneumonia DT-S in lung, trachea, and blood of mice and in proportion to the dose administration, and also increases the survival rate of mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Solid

White to off-white

[Poly (I:C):Kanamycin (1:1) (sodium)]

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Robert Field, et al. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun. 2010 Aug;24(6):996-1007.  [Content Brief]

  [2]. Besch R, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest. 2009 Aug;119(8):2399-411.  [Content Brief]

  [3]. Cheng YS, et al. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther. 2010 Dec 15;10(12):1219-23.  [Content Brief]